JP2013505030A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013505030A5 JP2013505030A5 JP2012530325A JP2012530325A JP2013505030A5 JP 2013505030 A5 JP2013505030 A5 JP 2013505030A5 JP 2012530325 A JP2012530325 A JP 2012530325A JP 2012530325 A JP2012530325 A JP 2012530325A JP 2013505030 A5 JP2013505030 A5 JP 2013505030A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- fragment
- variant
- derivative
- fusion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 19
- 229920001184 polypeptide Polymers 0.000 claims description 18
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 18
- 239000012634 fragment Substances 0.000 claims description 14
- 230000004927 fusion Effects 0.000 claims description 14
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 7
- 206010061218 Inflammation Diseases 0.000 claims description 6
- 230000004054 inflammatory process Effects 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 5
- 108090000481 Heparin Cofactor II Proteins 0.000 claims description 2
- 102100030500 Heparin cofactor 2 Human genes 0.000 claims description 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 2
- 230000014508 negative regulation of coagulation Effects 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 201000005665 thrombophilia Diseases 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
- 208000027866 inflammatory disease Diseases 0.000 claims 4
- 208000035473 Communicable disease Diseases 0.000 claims 3
- 206010040047 Sepsis Diseases 0.000 claims 3
- 230000005856 abnormality Effects 0.000 claims 3
- 230000002757 inflammatory effect Effects 0.000 claims 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical group N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims 2
- 206010040070 Septic Shock Diseases 0.000 claims 2
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims 2
- 208000007536 Thrombosis Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 230000001112 coagulating effect Effects 0.000 claims 2
- 230000015271 coagulation Effects 0.000 claims 2
- 238000005345 coagulation Methods 0.000 claims 2
- 208000009190 disseminated intravascular coagulation Diseases 0.000 claims 2
- 230000002458 infectious effect Effects 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 230000002980 postoperative effect Effects 0.000 claims 2
- 230000009885 systemic effect Effects 0.000 claims 2
- 206010003011 Appendicitis Diseases 0.000 claims 1
- 206010051548 Burn infection Diseases 0.000 claims 1
- 206010007882 Cellulitis Diseases 0.000 claims 1
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 206010011686 Cutaneous vasculitis Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 201000000297 Erysipelas Diseases 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 102000005720 Glutathione transferase Human genes 0.000 claims 1
- 108010070675 Glutathione transferase Proteins 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 208000007117 Oral Ulcer Diseases 0.000 claims 1
- 206010033078 Otitis media Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 206010067268 Post procedural infection Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 206010040943 Skin Ulcer Diseases 0.000 claims 1
- 208000007107 Stomach Ulcer Diseases 0.000 claims 1
- 108010090804 Streptavidin Proteins 0.000 claims 1
- 208000004732 Systemic Vasculitis Diseases 0.000 claims 1
- 206010044248 Toxic shock syndrome Diseases 0.000 claims 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 230000021736 acetylation Effects 0.000 claims 1
- 238000006640 acetylation reaction Methods 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000038016 acute inflammation Diseases 0.000 claims 1
- 230000006022 acute inflammation Effects 0.000 claims 1
- 230000010933 acylation Effects 0.000 claims 1
- 238000005917 acylation reaction Methods 0.000 claims 1
- 230000003044 adaptive effect Effects 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 230000029936 alkylation Effects 0.000 claims 1
- 238000005804 alkylation reaction Methods 0.000 claims 1
- 201000009961 allergic asthma Diseases 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 230000009435 amidation Effects 0.000 claims 1
- 238000007112 amidation reaction Methods 0.000 claims 1
- 230000000845 anti-microbial effect Effects 0.000 claims 1
- 208000002399 aphthous stomatitis Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 239000012620 biological material Substances 0.000 claims 1
- 229960002685 biotin Drugs 0.000 claims 1
- 235000020958 biotin Nutrition 0.000 claims 1
- 239000011616 biotin Substances 0.000 claims 1
- -1 carrier Substances 0.000 claims 1
- 201000001352 cholecystitis Diseases 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000007784 diverticulitis Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000032050 esterification Effects 0.000 claims 1
- 238000005886 esterification reaction Methods 0.000 claims 1
- 210000004392 genitalia Anatomy 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 206010023332 keratitis Diseases 0.000 claims 1
- 206010033072 otitis externa Diseases 0.000 claims 1
- 230000006320 pegylation Effects 0.000 claims 1
- 201000001245 periodontitis Diseases 0.000 claims 1
- 206010034674 peritonitis Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000003449 preventive effect Effects 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 206010039083 rhinitis Diseases 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 231100000397 ulcer Toxicity 0.000 claims 1
- 208000019206 urinary tract infection Diseases 0.000 claims 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0916578.8A GB0916578D0 (en) | 2009-09-22 | 2009-09-22 | Polypeptides and uses thereof |
| GB0916578.8 | 2009-09-22 | ||
| PCT/GB2010/001780 WO2011036444A1 (en) | 2009-09-22 | 2010-09-21 | Heparin cofactor ii fragments with anti-inflammatory and anti-coagulant activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013505030A JP2013505030A (ja) | 2013-02-14 |
| JP2013505030A5 true JP2013505030A5 (enExample) | 2015-06-18 |
Family
ID=41278086
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012530325A Pending JP2013505030A (ja) | 2009-09-22 | 2010-09-21 | 抗炎症及び抗凝固活性を有するヘパリンコファクターｉｉ断片 |
| JP2012530326A Abandoned JP2013505286A (ja) | 2009-09-22 | 2010-09-22 | ポリペプチド及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012530326A Abandoned JP2013505286A (ja) | 2009-09-22 | 2010-09-22 | ポリペプチド及びその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9169315B2 (enExample) |
| EP (2) | EP2480244A1 (enExample) |
| JP (2) | JP2013505030A (enExample) |
| CN (2) | CN102655874B (enExample) |
| AU (2) | AU2010299630A1 (enExample) |
| BR (2) | BR112012006502A2 (enExample) |
| CA (2) | CA2774288A1 (enExample) |
| EA (1) | EA201200515A1 (enExample) |
| GB (1) | GB0916578D0 (enExample) |
| IN (2) | IN2012DN02981A (enExample) |
| MX (1) | MX2012003425A (enExample) |
| WO (2) | WO2011036444A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2748616B1 (en) * | 2011-08-23 | 2018-08-08 | Synapse B.V. | Thermostable inhibitors of activation of the blood clotting system through contact with foreign surfaces. |
| RU2476231C1 (ru) * | 2011-10-11 | 2013-02-27 | Федеральное государственное бюджетное учреждение "Российский научный центр "Восстановительная травматология и ортопедия" имени академика Г.А. Илизарова" Министерства здравоохранения и социального развития Российской Федерации | Способ купирования некроза краев кожи послеоперационной раны после эндопротезирования голеностопного сустава |
| GB2500184A (en) * | 2012-03-12 | 2013-09-18 | Ximmune Ab | Polypeptide derived from helix A of heparin cofactor II |
| CN104292309B (zh) * | 2014-09-29 | 2017-04-12 | 广西中医药大学 | 一种小分子多肽 |
| WO2016104436A1 (ja) * | 2014-12-22 | 2016-06-30 | 国立大学法人 岡山大学 | サイトカインストーム抑制剤 |
| RU2606836C2 (ru) * | 2015-03-12 | 2017-01-10 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) | Антикоагулянтный, антитромбоцитарный и фибриндеполимеризационный комплекс на основе гепарина, способ его получения и применение |
| RU2610433C1 (ru) * | 2016-02-17 | 2017-02-10 | Людмила Анисимовна Ляпина | Антикоагулянт |
| CN107875372A (zh) * | 2017-12-20 | 2018-04-06 | 辽宁师范大学 | 重组肽rLj‑112在制备协同肝素抗凝药物中的应用 |
| CN108338163A (zh) * | 2018-03-28 | 2018-07-31 | 陈太师 | 一种持效型杀菌灭藻剂的制备方法 |
| EP3808362A4 (en) * | 2018-05-31 | 2022-03-09 | National University Corporation Okayama University | REACTIVE OXYGEN PRODUCTION INHIBITORS AND/OR SCAVENGING PROMOTERS |
| JP7340862B2 (ja) * | 2018-06-28 | 2023-09-08 | 国立大学法人 岡山大学 | 好中球貪食能増強剤 |
| EP3837549A1 (en) * | 2018-08-16 | 2021-06-23 | Roche Diagnostics GmbH | Circulating tfpi-2 (tissue factor pathway inhibitor 2) in the assessment of atrial fibrillation and anticoagulation therapy |
| CN109432513B (zh) * | 2018-12-12 | 2021-03-23 | 中国医科大学 | 一种具有抗血栓再形成功能的生物材料及其制备方法 |
| US11904000B2 (en) | 2019-05-06 | 2024-02-20 | Brown University | Compositions and methods to enhance cutaneous wound healing |
| JP2023526880A (ja) * | 2020-05-26 | 2023-06-26 | ウニヴェルシテーツメディツィン・デア・ヨハネス・グーテンベルク－ウニヴェルシテート・マインツ | コロナウイルス感染症および関連する凝固障害を処置するための方法および組成物 |
| CN114113601A (zh) * | 2020-08-25 | 2022-03-01 | 张曼 | 尿液肝素辅因子ii及其多肽片段在烧伤中的应用 |
| CN114292765B (zh) * | 2021-09-24 | 2023-04-07 | 江西康之康中药科技有限公司 | 枯草芽孢杆菌纳豆亚种r3及其在发酵水蛭低温干燥品中的应用 |
| CN114886116B (zh) * | 2022-03-18 | 2023-11-21 | 广东丸美生物技术股份有限公司 | 一种调理育龄女性健康的组合物及其制备方法和饮料及应用 |
| CN116510074A (zh) * | 2023-03-13 | 2023-08-01 | 西南交通大学 | 一种胆碱磷酸功能化可植入钛支架的制备方法 |
| CN116836233B (zh) * | 2023-08-31 | 2023-11-14 | 中国农业大学 | 抗炎活性多肽及其应用 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| SE459005B (sv) | 1985-07-12 | 1989-05-29 | Aake Rikard Lindahl | Saett att framstaella sfaeriska polymerpartiklar |
| US5102995A (en) * | 1989-10-20 | 1992-04-07 | Washington University | Dna encoding modified heparin cofactor ii |
| US5118793A (en) * | 1989-10-20 | 1992-06-02 | Washington University | Modified heparin cofactor II |
| US5643872A (en) | 1989-10-23 | 1997-07-01 | Smithkline Beecham Corporation | Cyclic anti-aggregatory peptides |
| AU1873092A (en) * | 1991-04-09 | 1992-11-17 | Brigham And Women's Hospital | Chimeric molecule with plasminogen activator activity and affinity for atherosclerotic plaques |
| US6008058A (en) | 1993-06-18 | 1999-12-28 | University Of Louisville | Cyclic peptide mixtures via side chain or backbone attachment and solid phase synthesis |
| US5589359A (en) | 1994-08-05 | 1996-12-31 | Chiron Corporation | Chimeric proteins |
| US5712247A (en) * | 1995-02-21 | 1998-01-27 | University Of North Carolina | Use of lactoferrin to modulate and/or neutralize heparin activity |
| CA2192782C (en) | 1995-12-15 | 2008-10-14 | Nobuyuki Takechi | Production of microspheres |
| JPH09176040A (ja) * | 1995-12-27 | 1997-07-08 | Green Cross Corp:The | ヘパリンコファクターｉｉの医薬用途 |
| US6946439B2 (en) * | 1997-02-06 | 2005-09-20 | Entre Med, Inc. | Compositions and methods for inhibiting cellular proliferation comprising TFPI fragments |
| WO1999043810A1 (en) * | 1998-02-27 | 1999-09-02 | The University Of North Carolina At Chapel Hill | Mutant heparin cofactor ii |
| WO2001036632A2 (en) * | 1999-11-17 | 2001-05-25 | Compugen Ltd. | Variants of alternative splicing |
| WO2003007689A2 (en) * | 2001-07-20 | 2003-01-30 | Eidgenoessische Technische Hochschule Zurich (Ethz) | Compositions and methods for use of bioactive agents derived from sulfated and sulfonated amino acids |
| GB0131112D0 (en) | 2001-12-31 | 2002-02-13 | Univ London Pharmacy | Block copolymers |
| AU2003243381A1 (en) * | 2002-05-31 | 2003-12-19 | University Of Utah Research Foundation | Variants of antithrombin iii |
| US8084036B2 (en) * | 2002-11-22 | 2011-12-27 | Nexbio, Inc. | Broad spectrum anti-viral therapeutics and prophylaxis |
| GB0316294D0 (en) | 2003-07-11 | 2003-08-13 | Polytherics Ltd | Conjugated biological molecules and their preparation |
| WO2005015206A2 (en) | 2003-08-08 | 2005-02-17 | Genova Ltd. | Secreted polypeptide species associated with cardiovascular disorders |
| EP1729791A2 (en) * | 2004-03-17 | 2006-12-13 | Chiron Corporation | Treatment of severe community-acquired pneumonia by admistration of tissue factor pathway inhibitor (tfpi) |
| US20050261241A1 (en) * | 2004-05-19 | 2005-11-24 | Celsus Biopharmaceuticals, Inc. | Use of dermatan sulfates and/or desulfated heparins to treat or prevent heparinoid-induced autoimmune responses |
| KR20080017021A (ko) * | 2005-05-06 | 2008-02-25 | 노바티스 아게 | 중증 박테리아 감염을 치료하기 위한 ｔｆｐｉ의 용도 |
| CA2615777A1 (en) * | 2005-07-22 | 2007-02-01 | Novartis Ag | Tfpi fragments as anti-microbial agents |
| EP3088522B1 (en) * | 2005-12-29 | 2017-11-29 | The Regents of the University of California | Methods and compositions related to mutant kunitz domain i of tfpi-2 |
| LT1981519T (lt) * | 2005-12-29 | 2018-04-25 | Dyax Corp. | Proteazės slopinimas |
| CA2637221A1 (en) * | 2006-02-10 | 2007-08-16 | Dermagen Ab | Novel antimicrobial peptides and use thereof |
| NZ579985A (en) * | 2007-04-13 | 2012-02-24 | Catalyst Biosciences Inc | Modified factor vii polypetides and uses thereof |
| US20090098207A1 (en) * | 2007-07-24 | 2009-04-16 | Nexbio, Inc. | Technology for the Preparation of Microparticles |
-
2009
- 2009-09-22 GB GBGB0916578.8A patent/GB0916578D0/en not_active Ceased
-
2010
- 2010-09-21 AU AU2010299630A patent/AU2010299630A1/en not_active Abandoned
- 2010-09-21 IN IN2981DEN2012 patent/IN2012DN02981A/en unknown
- 2010-09-21 CN CN201080052695.8A patent/CN102655874B/zh not_active Expired - Fee Related
- 2010-09-21 CA CA2774288A patent/CA2774288A1/en not_active Abandoned
- 2010-09-21 EA EA201200515A patent/EA201200515A1/ru unknown
- 2010-09-21 WO PCT/GB2010/001780 patent/WO2011036444A1/en not_active Ceased
- 2010-09-21 US US13/497,006 patent/US9169315B2/en not_active Expired - Fee Related
- 2010-09-21 MX MX2012003425A patent/MX2012003425A/es not_active Application Discontinuation
- 2010-09-21 BR BR112012006502A patent/BR112012006502A2/pt not_active IP Right Cessation
- 2010-09-21 JP JP2012530325A patent/JP2013505030A/ja active Pending
- 2010-09-21 EP EP10777056A patent/EP2480244A1/en not_active Withdrawn
- 2010-09-22 WO PCT/GB2010/001781 patent/WO2011036445A2/en not_active Ceased
- 2010-09-22 JP JP2012530326A patent/JP2013505286A/ja not_active Abandoned
- 2010-09-22 EP EP10777057A patent/EP2480564A2/en not_active Withdrawn
- 2010-09-22 CN CN2010800527096A patent/CN102639556A/zh active Pending
- 2010-09-22 CA CA2774296A patent/CA2774296A1/en not_active Abandoned
- 2010-09-22 US US13/497,195 patent/US20120189673A1/en not_active Abandoned
- 2010-09-22 IN IN3368DEN2012 patent/IN2012DN03368A/en unknown
- 2010-09-22 BR BR112012006501A patent/BR112012006501A8/pt not_active IP Right Cessation
- 2010-09-22 AU AU2010299631A patent/AU2010299631A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013505030A5 (enExample) | ||
| JP2013505286A5 (enExample) | ||
| WO2011036444A4 (en) | Heparin cofactor ii fragments with anti-inflammatory and anti-coagulant activity | |
| Bals et al. | The innate immune system in cystic fibrosis lung disease | |
| Gallo et al. | Biology and clinical relevance of naturally occurring antimicrobial peptides | |
| JP5330230B2 (ja) | 改良型抗菌ペプチド | |
| Gallo et al. | Endogenous production of antimicrobial peptides in innate immunity and human disease | |
| Leth-Larsen et al. | Surfactant protein D (SP-D) serum levels in patients with community-acquired pneumonia | |
| Kishore et al. | Surfactant proteins SP-A and SP-D in human health and disease | |
| JP6007106B2 (ja) | 炎症性腸疾患（ｉｂｄ）及び過敏性腸症候群（ｉｂｓ）の予防及び治療のための組換体プロバイオティック細菌 | |
| JP2009526045A (ja) | 新規抗菌ペプチド及びその使用 | |
| US20130052258A1 (en) | Polypeptides and uses thereof | |
| JP2009526046A (ja) | 新規分子 | |
| Żelechowska et al. | Endogenous antimicrobial factors in the treatment of infectious diseases | |
| KR20070108142A (ko) | 신규한 항미생물성 펩타이드 | |
| Ishikawa et al. | Precursor processing of human defensin-5 is essential to the multiple functions in vitro and in vivo | |
| JP2008505852A5 (enExample) | ||
| CN108165567A (zh) | 人溶菌酶基因的合成及其表达产物的构建方法 | |
| Manolov et al. | Moraxella-dependent α1-antichymotrypsin neutralization: A unique virulence mechanism | |
| Saxena | Lung surfactant: The indispensable component of respiratory mechanics | |
| JPWO2007049770A1 (ja) | 緑膿菌の外膜タンパク質ｐａ５１５８ | |
| Craig-Barnes | Interactions of Surfactant Protein D with the Glycoproteins Ovalbumin and Alpha-2-Macroglobulin | |
| Bresner | The Quantity and Structural Quality of SP-A and SP-D Present in the Airways of Influenza-Infected Patients | |
| Glucosamine | Mannose-Binding Lectin Recognizes | |
| Thursz et al. | Host surfactant proteins in microbial recognition |